Item 5.07. Submission of Matters to a Vote of Security Holders

At the Protagonist Therapeutics, Inc. (the "Company") 2021 Annual Meeting of Stockholders (the "Annual Meeting") held on May 27, 2021, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 14, 2021. The results of the matters voted upon at the meeting were:

Proposal 1 - To elect the three Class II directors named below to serve until the 2024 Annual Meeting of Stockholders. Each of the three named nominees was so elected, with the votes thereon at the Annual Meeting as follows:





                                                   Final Voting Results
Nominees                                    For       Withheld    Broker Non-Votes
Sarah A. O'Dowd                          38,323,022    306,101       2,984,809
William D. Waddill                       34,282,286   4,346,837      2,984,809

Lewis T. "Rusty" Williams, M.D., Ph.D. 34,296,520 4,332,603 2,984,809

Proposal 2 - To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:





              Final Voting Results
   For       Against   Abstain   Broker Non-Votes
41,608,911    4,897      124            -

No other matters were submitted for stockholder action.

© Edgar Online, source Glimpses